Clinical characteristics of patients with refractory/relapsed disease, as assessed by WB
. | No. . | % . |
|---|---|---|
| Total | 30 | 100 |
| Mean age, y (range) | 59 (42-77) | NA |
| Sex, female | 16 | 53.0 |
| M component | ||
| IgG | 23 | 76.6 |
| IgA | 3 | 10.0 |
| Light chain | 3 | 10.0 |
| Nonsecretory | 1 | 3.4 |
| K | 19 | 65.5 |
| Previous lines of treatment | ||
| Conventional | 14 | 46.7 |
| Thalidomide plus conventional | 8 | 26.7 |
| Autologous transplantation | 8 | 26.6 |
| Treatment after COX-2 assessment | ||
| Thalidomide-containing therapy | 7 | 23.4 |
| Bortezomib-containing therapy | 1 | 3.3 |
| Chemotherapy only | 10 | 33.3 |
| Autologous or allogeneic SCT | 12 | 40.0 |
. | No. . | % . |
|---|---|---|
| Total | 30 | 100 |
| Mean age, y (range) | 59 (42-77) | NA |
| Sex, female | 16 | 53.0 |
| M component | ||
| IgG | 23 | 76.6 |
| IgA | 3 | 10.0 |
| Light chain | 3 | 10.0 |
| Nonsecretory | 1 | 3.4 |
| K | 19 | 65.5 |
| Previous lines of treatment | ||
| Conventional | 14 | 46.7 |
| Thalidomide plus conventional | 8 | 26.7 |
| Autologous transplantation | 8 | 26.6 |
| Treatment after COX-2 assessment | ||
| Thalidomide-containing therapy | 7 | 23.4 |
| Bortezomib-containing therapy | 1 | 3.3 |
| Chemotherapy only | 10 | 33.3 |
| Autologous or allogeneic SCT | 12 | 40.0 |
WB indicates Western blotting; NA, not applicable SCT, stem cell transplantation.